pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

pre-IPO PHARMA NEWS

Business

adaptive-phage-therapeutics

09/30/21

Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases
xnk-therapeutics

09/29/21

XNK Therapeutics targets broader pipeline opportunities for its NK cell therapy
oblique-therapeutics

09/28/21

Oblique Therapeutics announces achievement of key milestone in its aKRAS-mAb program and Abiprot platform
anji-pharma

09/28/21

Anji Pharma Secures $70 Million to Deploy Dynamic Equity and Further Build a Global Medicines Company
union-therapeutics

09/28/21

UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions
recode-therapeutics

09/28/21

ReCode Therapeutics Announces Participation in Upcoming October Investor Conferences
viiv-healthcare

09/28/21

FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
viiv-healthcare

09/28/21

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals
cycle-pharma

09/28/21

Cycle Pharmaceuticals launches SAJAZIRTM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)
union-therapeutics

09/27/21

Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions
neurophth

09/27/21

Neurophth Announces the Completion of GMP Manufacturing Facility for Gene Therapy Products According to International Standards
delix-therapeutics

09/27/21

Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders
ksq-therapeutics

09/27/21

KSQ Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
ambys-medicines

09/27/21

Ambys Medicines Announces Presentation on Novel Liver Cell Therapy Platform for Severe Liver Diseases, and Opening of its cGMP Cell Therapy Manufacturing Facility
jasper-therapeutics

09/24/21

Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy
quell-therapeutics

09/23/21

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult
frontier-medicines

09/23/21

Frontier Medicines to Present at the Cantor Global Healthcare Conference
boundless-bio

09/23/21

Boundless Bio to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
second-genome

09/23/21

Second Genome Announces Research Collaboration with Virginia Commonwealth University to Identify a Non-Invasive NASH Composite Biomarker
surrozen

09/23/21

Surrozen to Present at Cowen and Company 40th Annual Health Care Conference

Science


precigen-actobio

10/01/21

Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
gyroscope-therapeutics

09/30/21

Gyroscope Therapeutics Announces Presentation of Positive Interim Phase I/II Data for Investigational Gene Therapy GT005 at Retina Society Annual Scientific Meeting
pharmazz

09/29/21

US FDA approved IND submitted by Pharmazz, Inc. to initiate a phase III clinical trial of centhaquine in patients with hypovolemic shock
viiv-healthcare

09/29/21

ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs
kineta

09/28/21

Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
camp4

09/27/21

CAMP4 Presents First Preclinical Data Demonstrating the Therapeutic Potential of its RNA Actuating Platform at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
venatorx-pharmaceuticals

09/27/21

Venatorx Pharmaceuticals to Present Data at IDWeek 2021
jw-therapeutics

09/27/21

JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129 USA - English USA - English USA - English España - español Deutschland - Deutsch France - Français
transcenta

09/26/21

Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002
SAb-biotherapeutics

09/24/21

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
codagenix

09/22/21

Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies
boundless-bio

09/22/21

Boundless Bio Announces Upcoming Presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021
clover-biopharmaceuticals

09/22/21

COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial
immunicom

09/21/21

Immunicom Introduces 2nd Product of Immunopheresis Therapy Platform Designed to Suppress Cancer Progression and Overcome Therapeutic Resistance
hemoshear-therapeutics

09/21/21

HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline
huyabio

09/21/21

HUYABIO Announces First Patient Treated in a Pivotal Study of HBI-8000 Combined with Opdivo (nivolumab) in Patients with Advanced Melanoma
neurelis

09/20/21

Neurelis Initiates Study Of VALTOCO (diazepam nasal spray) In Children With Seizure Clusters Aged Two To Five
humacyte

09/20/21

Humacyte Announces Issuance of Three Additional U.S. Patents Covering its Proprietary Universally Implantable Bioengineered Human Tissue Platform
arecor

09/20/21

Arecor announces Phase 1 of AT247 at ADA
arecor

09/20/21

Arecor Announces Positive Headline Results From First Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Diabetes

People

m6p-therapeutics

09/30/21

Dr. Stuart Kornfeld, M6P Therapeutics’ Co-Founder, to Receive the Roscoe O. Brady Award For Innovation and Accomplishment at WORLDSymposium™ 2022

curebase

09/30/21

Curebase Solutions Supports Another InBios FDA Emergency Use Authorization for COVID-19 IgG Antibody Rapid Test

phosplatin-therapeutics

09/29/21

Phosplatin Therapeutics Appoints Industry Veteran Elizabeth Tallett to Board of Directors

aura-biosciences

09/29/21

Aura Biosciences Expands Executive Leadership Team and Board of Directors

immunicom

09/28/21

Immunicom’s Alternative Subtractive Cancer Therapy Recognized with Zoom’s Healthcare Innovation Award

pantheryx

09/28/21

PanTheryx Welcomes Wilderness Medicine Practitioner Stuart Harris to its Board of Directors

SAb-biotherapeutics

09/28/21

SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

tectonic-therapeutic

09/27/21

Fierce Biotech Names Tectonic Therapeutic as One of Its “Fierce 15” Biotech Companies of 2021

elevar-therapeutics

09/27/21

Elevar Therapeutics Announces New Appointments to Strengthen Its Senior Leadership Team

recode-therapeutics

09/27/21

ReCode Therapeutics Appoints Nicholas P. France, M.D., as Senior Vice President of Clinical Development

ribon-therapeutics

09/27/21

Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech

adaptive-phage-therapeutics

09/23/21

Adaptive Phage Therapeutics Appoints Michele Wales, Ph.D., J.D., as Chief Legal Officer

curebase

09/23/21

Curebase Hires Katri Langel as Senior Director of Program Development for Europe

surrozen

09/23/21

Surrozen Expands Board of Directors with Appointment of Shao-Lee Lin, M.D., Ph.D.

surrozen

09/23/21

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

tectonic-therapeutic

09/22/21

Tectonic Therapeutic Named an “Endpoints 11” Winner

vividion-therapeutics

09/22/21

Vividion Therapeutics Announces Formation of Scientific Advisory Board

nimbus-therapeutics

09/21/21

Nimbus Therapeutics Appoints Ian Sanderson, MBA, as Chief Financial Officer

jcyte

09/21/21

jCyte Announces Appointment of Dr. Rebecca Kammer as Vice President of Clinical Operations

immuneid

09/21/21

ImmuneID Appoints Veteran Biotech Executive James S. Scibetta as CEO

anima-biotech

09/21/21

Anima Biotech To Participate In Fireside Chat During The Undruggable Leaders Forum

vigeo-therapeutics

09/21/21

Vigeo Therapeutics Provides Clinical Update for Lead Asset VT1021 and Welcomes New Chief Executive Officer